AR086924A1 - Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion - Google Patents
Anticuerpos anti-receptor de epo humano y los metodos para su utilizacionInfo
- Publication number
- AR086924A1 AR086924A1 ARP120102104A ARP120102104A AR086924A1 AR 086924 A1 AR086924 A1 AR 086924A1 AR P120102104 A ARP120102104 A AR P120102104A AR P120102104 A ARP120102104 A AR P120102104A AR 086924 A1 AR086924 A1 AR 086924A1
- Authority
- AR
- Argentina
- Prior art keywords
- epo receptor
- human
- antibody
- lpgpggsvdiv
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Describe también un anticuerpo que se une de forma especifica al receptor de la EPO humano, en el que el anticuerpo se une al fragmento del receptor de la EPO LPGPGGSVDIV (Id. de Sec. Nº 01) pero no se une específicamente a una proteína que puede obtenerse a partir de células endoteliales humanas que posee un peso molecular de alrededor de 66 kD.Reivindicación 1: Un método para la detección in vitro del receptor de la EPO humano que comprende los siguientes pasos: determinar in vitro la presencia del receptor de la EPO humano en una muestra mediante la incubación de la muestra con un anticuerpo contra el receptor de la EPO que se une de forma específica al fragmento del receptor de la EPO humano LPGPGGSVDIV (Id. de Sec. Nº 01) y así se detecta in vitro el receptor de la EPO humano, en el que el anticuerpo del receptor de la EPO que se une de forma específica al fragmento del receptor de la EPO LPGPGGSVDIV (Id. de Sec. Nº 01) no se une específicamente a una proteína que puede obtenerse a partir de células endoteliales humanas y que posee un peso molecular de alrededor de 66 kD. Reivindicación 5: La utilización de un anticuerpo que se une de forma específica al receptor de la EPO humano, que se caracteriza porque el anticuerpo se une al fragmento del receptor de la EPO LPGPGGSVDIV (Id. de Sec. Nº 01) y no se une específicamente a una proteína que puede obtenerse a partir de células endoteliales humanas y que posee un peso molecular de alrededor de 66 kD, para detectar el receptor de la EPO humano. Reivindicación 13: Una formulación farmacéutica que comprende el anticuerpo de cualquiera de las reivindicaciones de 2 a 4 y un transportador aceptable a nivel farmacéutico. Reivindicación 14: Un ácido nucleico aislado que codifica el anticuerpo de acuerdo con cualquiera de las reivindicaciones de 2 a 4. Reivindicación 15: Una célula huésped que comprende el ácido nucleico de la reivindicación 14. Reivindicación 17: La utilización de un anticuerpo de acuerdo con cualquiera de las reivindicaciones de 2 a 4 para el análisis del receptor de la EPO en una muestra de tejido o célula humanos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11170020 | 2011-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086924A1 true AR086924A1 (es) | 2014-01-29 |
Family
ID=45044836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102104A AR086924A1 (es) | 2011-06-15 | 2012-06-14 | Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion |
Country Status (15)
Country | Link |
---|---|
US (2) | US8623666B2 (es) |
EP (1) | EP2721067B1 (es) |
JP (1) | JP5984919B2 (es) |
KR (1) | KR101629073B1 (es) |
CN (1) | CN103596984B (es) |
AR (1) | AR086924A1 (es) |
AU (1) | AU2012269075B2 (es) |
BR (1) | BR112013032235A2 (es) |
CA (1) | CA2837914A1 (es) |
HK (1) | HK1193615A1 (es) |
IL (1) | IL229764A0 (es) |
MX (1) | MX343117B (es) |
MY (1) | MY166974A (es) |
RU (1) | RU2013158627A (es) |
WO (1) | WO2012171996A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE053669T2 (hu) | 2012-12-05 | 2021-07-28 | Novartis Ag | Készítmények és eljárások EPO-t célzó antitestekre |
KR101539150B1 (ko) * | 2013-12-26 | 2015-07-27 | 가톨릭대학교 산학협력단 | 자가면역 항체 검출방법 및 이를 이용한 자가면역 항체 검출키트 |
US10839509B2 (en) | 2015-07-10 | 2020-11-17 | 3Scan Inc. | Spatial multiplexing of histological stains |
CN107922975B (zh) | 2015-08-12 | 2022-06-28 | 诺华股份有限公司 | 治疗眼科病症的方法 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4966852A (en) | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
IL87171A (en) * | 1987-11-23 | 1995-08-31 | Monsanto Co | ANDC of human tissue factor inhibitor |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
EP0776370B1 (en) | 1993-08-16 | 2006-04-19 | Jong Y. Lee | Human erythropoietin receptor fragment and antibodies thereto |
EP0702553A1 (en) | 1993-12-27 | 1996-03-27 | BAXTER INTERNATIONAL INC. (a Delaware corporation) | Water soluble non-immunogenic polyamide cross-linking agents |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
AU6163196A (en) | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
WO2000061637A1 (en) | 1999-04-14 | 2000-10-19 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
US6998124B1 (en) | 1999-04-14 | 2006-02-14 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
EP1074563A1 (en) | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
CA2385347C (en) | 1999-10-04 | 2009-12-15 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
IL151853A0 (en) | 2000-04-11 | 2003-04-10 | Genentech Inc | Multivalent antibodies and uses therefor |
US20040058393A1 (en) | 2000-04-17 | 2004-03-25 | Naoshi Fukishima | Agonist antibodies |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
WO2002033073A1 (fr) | 2000-10-20 | 2002-04-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps agoniste degrade |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
KR20040054669A (ko) | 2001-08-03 | 2004-06-25 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
WO2003085102A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
TWI320716B (en) | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
US20040071694A1 (en) | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP4351674B2 (ja) | 2002-12-16 | 2009-10-28 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体とその使用法およびその使用 |
EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
DE10344737B3 (de) | 2003-09-26 | 2004-08-26 | LAUKÖTTER, Karl-Heinz | Gegenkolbenmotor nach Art eines Zweitaktmotors |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
WO2005035778A1 (ja) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
RS57466B1 (sr) | 2003-11-05 | 2018-09-28 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
JPWO2005080562A1 (ja) * | 2004-02-23 | 2007-08-02 | 弘 山元 | 前立腺癌の判定方法 |
EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
US20050227289A1 (en) * | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
US20060018902A1 (en) | 2004-04-09 | 2006-01-26 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
CA2703154A1 (en) | 2007-10-25 | 2009-04-30 | Philogene, Inc. | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
US20090181037A1 (en) | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
ES2542033T3 (es) * | 2007-11-29 | 2015-07-29 | Molecular Health Gmbh | Receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso |
US8357501B2 (en) * | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
JP2012500818A (ja) | 2008-08-28 | 2012-01-12 | エフ.ホフマン−ラ ロシュ アーゲー | ヒトepo受容体に対する抗体 |
EP2356146A1 (en) | 2008-11-07 | 2011-08-17 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
CN102282174B (zh) | 2009-01-15 | 2014-02-26 | 弗·哈夫曼-拉罗切有限公司 | 抗人epo受体的抗体 |
CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
BRPI1007602A2 (pt) | 2009-05-27 | 2016-02-16 | Hoffmann La Roche | "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia" |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
-
2012
- 2012-06-14 CN CN201280029140.0A patent/CN103596984B/zh not_active Expired - Fee Related
- 2012-06-14 EP EP12728475.0A patent/EP2721067B1/en active Active
- 2012-06-14 AR ARP120102104A patent/AR086924A1/es unknown
- 2012-06-14 JP JP2014515188A patent/JP5984919B2/ja not_active Expired - Fee Related
- 2012-06-14 BR BR112013032235A patent/BR112013032235A2/pt not_active IP Right Cessation
- 2012-06-14 AU AU2012269075A patent/AU2012269075B2/en not_active Ceased
- 2012-06-14 MY MYPI2013004527A patent/MY166974A/en unknown
- 2012-06-14 MX MX2013013937A patent/MX343117B/es active IP Right Grant
- 2012-06-14 RU RU2013158627/10A patent/RU2013158627A/ru not_active Application Discontinuation
- 2012-06-14 CA CA2837914A patent/CA2837914A1/en not_active Abandoned
- 2012-06-14 US US13/517,826 patent/US8623666B2/en active Active
- 2012-06-14 KR KR1020137033166A patent/KR101629073B1/ko not_active IP Right Cessation
- 2012-06-14 WO PCT/EP2012/061288 patent/WO2012171996A1/en active Application Filing
-
2013
- 2013-12-02 IL IL229764A patent/IL229764A0/en unknown
- 2013-12-05 US US14/097,972 patent/US9187563B2/en not_active Expired - Fee Related
-
2014
- 2014-07-08 HK HK14106895.7A patent/HK1193615A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2012269075A1 (en) | 2013-05-02 |
CN103596984A (zh) | 2014-02-19 |
US20140193418A1 (en) | 2014-07-10 |
MY166974A (en) | 2018-07-27 |
IL229764A0 (en) | 2014-01-30 |
US20120321633A1 (en) | 2012-12-20 |
EP2721067A1 (en) | 2014-04-23 |
BR112013032235A2 (pt) | 2016-11-22 |
MX343117B (es) | 2016-10-25 |
US8623666B2 (en) | 2014-01-07 |
JP5984919B2 (ja) | 2016-09-06 |
JP2014528693A (ja) | 2014-10-30 |
HK1193615A1 (zh) | 2014-09-26 |
US9187563B2 (en) | 2015-11-17 |
EP2721067B1 (en) | 2019-07-31 |
KR101629073B1 (ko) | 2016-06-09 |
NZ617936A (en) | 2015-10-30 |
MX2013013937A (es) | 2013-12-16 |
CN103596984B (zh) | 2016-04-13 |
AU2012269075B2 (en) | 2015-05-21 |
CA2837914A1 (en) | 2012-12-20 |
RU2013158627A (ru) | 2015-07-20 |
WO2012171996A1 (en) | 2012-12-20 |
KR20140013076A (ko) | 2014-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021203746B2 (en) | T cell receptors recognizing MHC class II-restricted MAGE-A3 | |
EA202090652A1 (ru) | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras | |
EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
Rizvi et al. | Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection | |
WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
BR112014008849A2 (pt) | receptores quiméricos de antígeno anti-cd22 | |
AR102732A1 (es) | Moléculas de unión a antígeno biespecíficas activadoras de células t | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
BR112016027805A2 (pt) | receptores de células t do anti-papilomavírus humano 16 e7 | |
NI200900027A (es) | Anticuerpos monoclonales humanos específicos para light humanos antagonistas. | |
AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
CL2012000822A1 (es) | Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; metodo para reducir nivel de proteina viral. | |
JP2015533788A5 (es) | ||
MX2014011504A (es) | Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus. | |
CL2012002700A1 (es) | Anticuerpo humanizado capaz de logarse especificamente a receptores de quimioquina 4 (cxcr4); molecula de acido nucleico aislada que codifica dicho anticuerpo; vector y célula que comprenden dicho acido nucleico; composicion que comprende dicho anticuerpo; proceso de deteccion in vitro de la presencia y/o la ubicacion de un tumor que expresa cxcr4. | |
CY1115624T1 (el) | Μεθοδος ανιχνευσης σε καποιο βιολογικο δειγμα των ειδικων αντισωματων για τα αβ | |
AR086924A1 (es) | Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion | |
BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
BR112014020513A2 (pt) | Métodos e sistemas para amplificação de sinal de bioensaios | |
ATE489632T1 (de) | Antigennachweis | |
BR112017011545A2 (pt) | ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente | |
Goel et al. | Targeted disruption of a ring-infected erythrocyte surface antigen (RESA)-like export protein gene in Plasmodium falciparum confers stable chondroitin 4-sulfate cytoadherence capacity | |
AR087654A1 (es) | METODO DIAGNOSTICO DE ANIMALES VACUNADOS CON PESTIVIRUS QUIMERICO EN EL CUAL LA PROTEINA Eʳⁿˢ DEL VIRUS DE LA DIARREA VIRAL BOVINA (BVDV) ES REMPLAZADA POR PROTEINA Eʳⁿˢ DE PESTIVIRUS DE ANTILOPE AMERICANO | |
WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
MX2013004069A (es) | Antigenos inmunoreactivos de mycoplasma haemofelis e inmunoensayos de diagnostico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |